Soft tissue sarcoma (STS) · line 1 · Doxorubicin monotherapy (soft tissue sarcoma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-DOXORUBICIN-STS |
| ID | IND-STS-ADVANCED-1L-DOXORUBICIN |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-SOFT-TISSUE-SARCOMA |
| Sources | SRC-EORTC62012-JUDSON-2014 SRC-NCCN-SARCOMA |
Notes
MDT at specialized sarcoma center is strongly recommended before starting chemotherapy — histological subtype significantly affects regimen selection. Key subtype-specific alternatives to consider at MDT: - Leiomyosarcoma: gemcitabine+docetaxel has specific activity; may be preferred 2L - Myxoid liposarcoma: trabectedin particularly effective (YONDELIS) - Synovial sarcoma: ifosfamide-sensitive — AI preferred over dox alone at some centers - WD/DD liposarcoma: doxorubicin active; CDK4/MDM2 targeted therapy in trials - ASPS (alveolar soft part sarcoma): anti-VEGFR agents more active than anthracyclines
Used By
Algorithms
ALGO-STS-ADVANCED-1L- ALGO-STS-ADVANCED-1L
Indication
IND-STS-ADVANCED-1L-AI- IND-STS-ADVANCED-1L-AI